Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXCM NYSE:HAE NASDAQ:HQY NASDAQ:LNTH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXCMDexCom$72.47+1.7%$66.93$54.11▼$89.98$27.96B1.455.37 million shs8.57 million shsHAEHaemonetics$74.10+1.9%$63.61$47.31▼$87.32$3.37B0.56885,757 shs887,719 shsHQYHealthEquity$85.21-1.3%$84.76$72.76▼$106.60$7.12B0.211.01 million shs1.20 million shsLNTHLantheus$103.92+0.7%$92.37$47.25▼$107.99$6.77B-0.03956,656 shs1.09 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXCMDexCom-2.64%-4.73%+9.43%+5.89%-12.95%HAEHaemonetics-2.18%-7.65%+27.11%+23.47%+5.48%HQYHealthEquity+0.78%-3.78%+3.96%+6.41%-13.68%LNTHLantheus-1.75%+2.94%+10.80%+32.31%+32.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXCMDexCom$72.47+1.7%$66.93$54.11▼$89.98$27.96B1.455.37 million shs8.57 million shsHAEHaemonetics$74.10+1.9%$63.61$47.31▼$87.32$3.37B0.56885,757 shs887,719 shsHQYHealthEquity$85.21-1.3%$84.76$72.76▼$106.60$7.12B0.211.01 million shs1.20 million shsLNTHLantheus$103.92+0.7%$92.37$47.25▼$107.99$6.77B-0.03956,656 shs1.09 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXCMDexCom-2.64%-4.73%+9.43%+5.89%-12.95%HAEHaemonetics-2.18%-7.65%+27.11%+23.47%+5.48%HQYHealthEquity+0.78%-3.78%+3.96%+6.41%-13.68%LNTHLantheus-1.75%+2.94%+10.80%+32.31%+32.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXCMDexCom 2.92Moderate Buy$84.8317.06% UpsideHAEHaemonetics 2.64Moderate Buy$78.335.71% UpsideHQYHealthEquity 2.86Moderate Buy$110.5729.76% UpsideLNTHLantheus 2.73Moderate Buy$101.86-1.98% DownsideCurrent Analyst Ratings BreakdownLatest HAE, DXCM, HQY, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2026HAEHaemonetics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$84.006/15/2026HAEHaemonetics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$70.00 ➝ $85.006/15/2026DXCMDexCom Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$75.00 ➝ $88.006/10/2026DXCMDexCom UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$95.006/10/2026DXCMDexCom TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.00 ➝ $95.006/9/2026DXCMDexCom MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$75.00 ➝ $85.006/8/2026DXCMDexCom Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy$91.006/5/2026HQYHealthEquity Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)6/5/2026DXCMDexCom Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$85.00 ➝ $90.006/3/2026HQYHealthEquity Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$100.00 ➝ $108.006/1/2026DXCMDexCom Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)(Data available from 6/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXCMDexCom$4.82B5.80$2.74 per share26.42$7.04 per share10.29HAEHaemonetics$1.33B2.52$7.55 per share9.82$17.14 per share4.32HQYHealthEquity$1.31B5.42$5.25 per share16.24$24.49 per share3.48LNTHLantheus$1.54B4.39$6.32 per share16.45$16.43 per share6.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXCMDexCom$836.30M$2.3430.9723.841.1419.31%33.33%13.19%7/29/2026 (Estimated)HAEHaemonetics$97.31M$2.0236.6812.911.507.29%27.30%9.59%8/6/2026 (Estimated)HQYHealthEquity$215.20M$2.6731.9118.731.4417.25%14.75%9.22%9/1/2026 (Estimated)LNTHLantheus$233.56M$4.1525.0419.24N/A18.05%29.32%15.00%8/5/2026 (Estimated)Latest HAE, DXCM, HQY, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/28/2026Q1 2027HQYHealthEquity$1.11$1.24+$0.13$0.82$352.02 million$354.64 million5/7/2026Q4 2026HAEHaemonetics$1.28$1.29+$0.01-$0.44$336.83 million$346.35 million5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million4/30/2026Q1 2026DXCMDexCom$0.47$0.56+$0.09$0.51$1.17 billion$1.19 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDXCMDexComN/AN/AN/AN/AN/AHAEHaemoneticsN/AN/AN/AN/AN/AHQYHealthEquityN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXCMDexCom0.421.951.64HAEHaemonetics1.532.951.87HQYHealthEquity0.463.443.44LNTHLantheus0.472.832.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXCMDexCom97.75%HAEHaemonetics99.67%HQYHealthEquity99.55%LNTHLantheus99.06%Insider OwnershipCompanyInsider OwnershipDXCMDexCom0.28%HAEHaemonetics2.07%HQYHealthEquity1.60%LNTHLantheus1.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXCMDexCom11,000385.87 million384.79 millionOptionableHAEHaemonetics3,00945.45 million44.51 millionOptionableHQYHealthEquity2,81483.60 million82.26 millionOptionableLNTHLantheus1,19365.11 million64.00 millionOptionableHAE, DXCM, HQY, and LNTH HeadlinesRecent News About These CompaniesLantheus (NASDAQ:LNTH) Sets New 52-Week High - What's Next?June 17 at 4:09 AM | americanbankingnews.comLantheus Holdings, Inc. (NASDAQ:LNTH) Q4 2024 Earnings Call TranscriptJune 9, 2026 | msn.comLantheus Holdings, Inc. (LNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.comAssessing Lantheus Holdings (LNTH) Valuation After Strong Multi Month Share Price GainsJune 5, 2026 | finance.yahoo.comLantheus to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceJune 3, 2026 | globenewswire.comLantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI’s Image of the YearJune 2, 2026 | markets.businessinsider.comLantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI's Image of the YearJune 2, 2026 | globenewswire.comAnalysts Are Bullish on Top Healthcare Stocks: IQVIA Holdings (IQV), Lantheus (LNTH)May 27, 2026 | theglobeandmail.comLantheus to Present at the William Blair 46th Annual Growth Stock ConferenceMay 27, 2026 | globenewswire.comLantheus Holdings gains after report it's evaluating a sale after offerMay 23, 2026 | msn.comHow The Story On Lantheus Holdings (LNTH) Is Shifting With PYLARIFY And Pipeline ExpectationsMay 23, 2026 | finance.yahoo.comLantheus weighs potential $7 billion sale, Bloomberg News reportsMay 22, 2026 | reuters.comLantheus Highlights New Radiodiagnostic Data at the 2026 SNMMI Annual MeetingMay 21, 2026 | globenewswire.comLantheus Announces Presentation of Data at the 2026 American Society of Clinical Oncology ...May 19, 2026 | caledonianrecord.comCLantheus Announces Presentation of Data at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingMay 19, 2026 | globenewswire.comWe Think You Should Be Aware Of Some Concerning Factors In Lantheus Holdings' (NASDAQ:LNTH) EarningsMay 15, 2026 | finance.yahoo.comLantheus Holdings (LNTH) price target increased by 10.39% to 103.33May 15, 2026 | msn.comLantheus Holdings, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 15, 2026 | seekingalpha.comBig Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category LeadersMay 14, 2026 | 247wallst.comLNTH: Lantheus Reports 1Q:26 Financial and Operational ResultsMay 8, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 20263 Stocks Doing the Heavy Lifting in Healthcare’s ReboundBy Jessica Mitacek | June 18, 2026HAE, DXCM, HQY, and LNTH Company DescriptionsDexCom NASDAQ:DXCM$72.47 +1.24 (+1.74%) Closing price 04:00 PM EasternExtended Trading$73.44 +0.97 (+1.34%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.Haemonetics NYSE:HAE$74.10 +1.37 (+1.88%) Closing price 03:59 PM EasternExtended Trading$74.17 +0.07 (+0.09%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.HealthEquity NASDAQ:HQY$85.21 -1.12 (-1.30%) Closing price 04:00 PM EasternExtended Trading$82.50 -2.71 (-3.17%) As of 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts. It also provides investment platform; and online-only automated investment advisory services through Advisor, a Web-based tool. In addition, the company offers flexible spending accounts; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. It serves clients through a direct sales force; benefits brokers and advisors; and a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. HealthEquity, Inc. was incorporated in 2002 and is based in Draper, Utah.Lantheus NASDAQ:LNTH$103.92 +0.73 (+0.70%) Closing price 03:59 PM EasternExtended Trading$103.90 -0.02 (-0.02%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Jabil Just Gave Investors a Stronger Reason to Buy the Dip USA Rare Earth Just Moved Closer to Commercial Reality After an Initial Panic, Wall Street's Leaning Into Apple's New Siri AI CoreWeave Insider Sales Look Big, But Should Investors Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
